Why the study?
Does clopidogrel 75 mg/day reduce gastroduodenal mucosal damage compared to aspirin 325 mg/day in healthy volunteers?
Does clopidogrel 75 mg/day reduce gastroduodenal mucosal damage compared to aspirin 325 mg/day in healthy volunteers?
Short-term treatment with clopidogrel 75 mg/day does not induce gastroscopically evident erosions, unlike aspirin 325 mg/day, in healthy volunteers.
Answers are grounded in this paper and cite their sources.
Clopidogrel induces less gastroduodenal damage than aspirin; confirms superior short-term GI tolerability in volunteers and supports patient trials.
BACKGROUND: Clopidogrel is a new antiplatelet agent that offers increased protection over aspirin in preventing vascular ischaemic events in patients with symptomatic atherosclerosis. In a large, randomized, international study of clopidogrel and aspirin (n = 19,185 patients) clopidogrel was associated with a lower incidence of gastrointestinal adverse events, including gastrointestinal haemorrhage and hospitalizations because of gastrointestinal haemorrhage. The aim of the study was to determine whether macroscopic differences in the gastric mucosa between aspirin- and clopidogrel-treated subjects could be detected by gastroscopy after short-term treatment. METHODS: Thirty-six healthy volunteers were randomized in a double-blind, double-dummy, parallel design, to 75 mg/day of clopidogrel or 325 mg/day of aspirin for 8 days. Gastroscopy was performed at base line before administration of study drug and directly after treatment completion. Gastroduodenal effects were measured in accordance with a modified Lanza scale. RESULTS: At base line no difference between the groups was detected (median Lanza score, 0.0 in both groups). At the end of treatment the aspirin group showed a median score of 7.5, and the clopidogrel group showed an unchanged median score of 0.0 (P < 0.001). In the aspirin group 13 individuals reported 19 adverse events versus 8 individuals and 13 adverse events for clopidogrel, with approximately half of the adverse events being gastrointestinal in each group. No serious adverse events were reported. CONCLUSION: In contrast to aspirin, short-term treatment with clopidogrel does not induce macroscopic changes in the gastroduodenal mucosa. The study results show that in patients without gastroduodenal disease clopidogrel, but not aspirin, does not induce any gastroscopically evident erosions during short-term treatment.
No takes yet. Share an insight, caveat, or question.
Frans Thomas Fork (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: